HRSA Will Still Fine Drug Makers Despite Revoking 340B Advisory Opinion

By Gabrielle Wanneh / June 22, 2021 at 3:09 PM

HHS told a federal court it will proceed with fines against pharmaceutical makers that restrict 340B discounts for drugs dispensed via contract pharmacies, even though the department scrapped a controversial advisory opinion on the issue.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.